*J.P. Morgan Asia FTM 22 May 26 China Healthcare: AI in drug development; Samsung Bio: Labor disputes; KEP: u/g to OW; Thai Consumer: Solid 1Q prints; NVDA 1Q key takes; SK: Raise PT to street high W870K

Research evidence excerpt

*J.P. Morgan Asia FTM 22 May 26 China Healthcare: AI in drug development; Samsung Bio: Labor disputes; KEP: u/g to OW; Thai Consumer: Solid 1Q prints; NVDA 1Q key takes; SK: Raise PT to street high W870K

Asia Pacific Equity Research

This material is neither intended to be distributed to Mainland China investors nor to provide securities

investment consultancy services within the territory of Mainland China. This material or any portion hereof

may not be reprinted, sold or redistributed without the written consent of J.P. Morgan.

Asia First to Market 22 May 2026

Top Stories

China Healthcare (Yang Huang)

Global China Summit Takeaways (Day 2): AI applications in early and late drug development; China

pharma panel

Day 2 key takeaways are: 1) WuXi AppTec reiterated its FY26E guidance, but we expect potential raise; 2)

XtalPi is expanding its AI-driven drug discovery ecosystem through flexible partnerships and automated lab

capabilities; 3) Tigermed is actively integrating AI across its clinical operations to optimize costs and

address ongoing pricing pressures; 4) Yifeng’s same-store sales recovery is on track, with management

guiding to 5%+ SSG (same store growth) in 2026; 5) Innovent’s management expressed confidence in

achieving a CAGR of 15%~20% from 2027-2030.

Samsung Biologics (207940.KS, OW – W1,381,000), South Korea (Jihyun Cho)

Long-held disputes with labor unions, but awaiting near-term settlements; PT cut to W2,200K,

remain OW

Samsung Biologics’ labor dispute remains unresolved following employees’ return from a five-day full-scale

strike (May 1-5), with work-to-rule actions (no overtime/holiday shifts) still in place. While Samsung

Electronics’ wage settlement yesterday is a modest positive read-across for a potential near-term resolution,